Vanderbilt Brain Tumor Center
Our Neuro-Oncology Team
Adult Brain Tumors:
Each year in the United States over 100,000 people are diagnosed with a primary or metastatic brain tumor. Currently, patients with brain tumors are treated with surgery, chemotherapy, radiation therapy or a combination approach. There are over 100 different types of brain tumors - benign and malignant - and the treatment for each varies considerably. Because the treatment of brain tumors is so specialized, it is important to have a neuro-oncologist involved to coordinate care.
Paul L. Moots, M.D.
Dr. Paul Moots is an Associate Professor of Neurology and is the Director of the Adult Neuro-Oncology Program. He completed a fellowship at the Sloan-Kettering Memorial Hospital and joined the Vanderbilt faculty in 1987. His practice is focused on caring for patients with brain and spinal cord tumors. He has special expertise in the treatment of brain tumors using chemotherapy and is pioneering new therapies for treatment of brain cancer.
Link to CV
Pediatric Brain Tumors:
Brain tumors are the leading cause of cancer death in children under the age of 20, and are the third leading cause of cancer death in young adults ages 20-39.The Pediatric Brain Tumor program is affiliated with the Vanderbilt Children's Hospital. This is one of the foremost children's hospitals in the country and provides comprehensive, state of the art treatment for children with cancer. The Vanderbilt Brain Tumor Center is fortunate to have an entire team devoted to the care of children with brain cancer.
John F. Kuttesch, Jr., M.D., Ph.D.
Dr. Kuttesch joined the Monroe Carell Jr. Children's Hospital and Vanderbilt-Ingram Cancer Center in 2002. His education includes the following: Ph.D. (Pharmacology and Toxicology), University of Texas Medical Branch in Galveston; medical degree, UT Medical School at Houston; residency in Pediatrics, Vanderbilt University School of Medicine; and fellowship in Hematology-Oncology, St. Jude Children's Hospital in Memphis. His recent experience includes associate professor in Pediatrics at the University of Texas-M.D. Anderson Cancer Center in Houston; prior to that appointment, assistant member at St. Jude Children's Hospital and Assistant Professor of Pediatrics at the University of Tennessee College of Medicine in Memphis. His clinical interests treatment of brain tumors in children, which as a group represent the most common solid tumor among children and the second leading childhood cancer behind leukemia, and novel therapeutic approaches for children with recurrent tumors. Kuttesch was recruited to develop the pediatric component of the Brain Tumor Center at Vanderbilt. His research interests include development and evaluation of new therapies for childhood brain tumors, including targeted molecular therapies to be used alone or in combination with other approaches.
